GenScript ProBio
Piscataway, NJ · Nanjing, CN
Program data pending ClinicalTrials.gov matching
· Last scored 2026-03-15
71.2
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (8)
Quick Facts: GenScript ProBio
- Signal Score
- 71.2/100 (as of 2026-03-15)
- Quality Compliance
- Assessment pending
- Headquarters
- Piscataway, NJ · Nanjing, CN
- Modalities
- CAR-T, Cell Therapy
- Active CGT Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CGT manufacturing intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
86.8
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Source: ClinicalTrials.gov
No clinical trial matches found for this manufacturer · Operational score requires ClinicalTrials.gov data
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
63.0
2 CGT manufacturing sites
Sites: Piscataway, NJ, Nanjing, CN
Source: SEC EDGAR, press monitoring, company profiles
2 CGT manufacturing sites
StatusConstrained
2 CGT manufacturing sites
Sites: Piscataway, NJ, Nanjing, CN
Recent Press8 articles
2 CGT manufacturing sites
Recent News 8 articles
GenScript reports strong fiscal 2025 results from platform strategy - Vietnam Investment Review - VIR
GenScript reports strong fiscal 2025 results from platform strategy Vietnam Investment Review - VIR
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership - Indian Pharma Post
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership Indian Pharma Post
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth - Bolsamania
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth Bolsamania
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership - Indian Pharma Post
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership Indian Pharma Post
GenScript opens its first European mRNA production site - Scientist Live
GenScript opens its first European mRNA production site Scientist Live
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub - BioSpace
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub BioSpace
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub - The AI Journal
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub The AI Journal
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub - BeBeez International
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub BeBeez International
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: